Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy

Size: px
Start display at page:

Download "Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy"

Transcription

1 Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado Schools of Pharmacy and Medicine Presenter Disclosure Financial Disclosure: There are no financial or other relationships to disclose related to this presentation Unlabeled/Unapproved Uses Disclosure: None Objectives Describe the types of psychologic disorders that heart failure patients may experience, including depression, anxiety, and PTSD. Discuss the various treatment options for psychologic disorders in the heart failure patient. 1

2 Depression Depression Across the Spectrum Trends in Cardiovascular Medicine 2015; 25(7): Hypotheses of Depression in HF J Physiol Pharmacol 2006 ;57 Suppl 11:

3 Hypotheses of Depression in HF J Physiol Pharmacol 2006 ;57 Suppl 11:5-29. Prevalence of Depression in HF J Am Coll Cardiol 2006;48: Prevalence of Depression in HF J Am Coll Cardiol 2006;48:

4 Depression/HF/Mortality Effect sizes and 95% confidence intervals among studies reporting associations between depression and mortality and secondary events (8 studies) J Am Coll Cardiol 2006;48: Depression/HF/Mortality Circ Heart Fail 2013; 6: Depression/HF/Mortality Circ Heart Fail 2015; 8:

5 Depression/HF/Adherence Clin Nurs Res. 2014; 23(3): Depression/HF/Adherence Medication adherent without depressive symptoms Medication adherent with depressive symptoms Medication nonadherent without depressive symptoms Medication nonadherent with depressive symptoms J Card Fail. 2013; 19(15): J Am Coll Cardiol 2010; 56(9):

6 SADHART-HF Change in HDRS from Baseline to Week 12 J Am Coll Cardiol 2010; 56(9): SADHART-HF Fatal and Nonfatal Events Through Week 12 J Am Coll Cardiol 2010; 56(9): SADHART-HF Fatal and Nonfatal Events Long Term J Am Coll Cardiol 2010; 56(9):

7 MOOD-HF MOOD-HF 7

8 MOOD-HF MOOD-HF MOOD-HF 8

9 MOOD-HF MOOD-HF MOOD-HF 9

10 MOOD-HF Screening Tools Rated on a 4 point Likert Scale from 0 (not at all) to 3 (nearly every day): range 0-6 A cut off > 3 optimal balance between sensitivity and specificity for major depression disorder In cardiac patients, a cut-off >2 exhibits an optimal balance between sensitivity and specificity Treatment Phases 10

11 Treatment Phases Symptoms to Pharmacology Mechanism of Action 11

12 Receptor Serotonin Receptors Function 1A, 1B, 1D, 1E, 1F Anxiety, aggression, sexual behavior, appetite, vasoconstriction 2A, 2B, 2C 2A: inhibits dopamine release; mediates anxiety, agitation, hallucinations, sexual behavior, weight gain/loss 2B: Smooth muscle (GI tract), cardiovascular function 2C: inhibits dopamine and norepinephrine release; mediates appetite, anxiety, mood, GI motility, sexual behavior, thermoregulation, weight gain/loss 3 Chemoreceptor trigger zone, emesis, GI/bowel motility, nausea, memory 4 Cardiac repolarization (seizure susceptibility), respiration, gastric emptying, oesophageal peristalsis, appetite, anxiety 5A, 5B Locomotion, anxiety, sleep, cognition, thermoregulation, respiration, mood, memory Pharmacology Pharmacology

13 Cardiac Side Effects Progess Cardiovasc Dis 2016; 58 (5): Cardiac Side Effects Inter J Cardiol. 2010; 140(1): Drug-Drug Interactions Inhibition of Cytochrome P450 Progess Cardiovasc Dis 2016; 58 (5):

14 Drug-Drug Interactions Progess Cardiovasc Dis 2016; 58 (5): Drug-Disease Interactions Avoid with Congenital Long QTc Progess Cardiovasc Dis 2016; 58 (5): Anxiety 14

15 Symptoms to Pharmacology Contribution to CVD Am J Cardiol 2016; 118 (4): Guideline Recommendations Treatment Options First Line Medications SSRI and SNRI FDA approved Venlafaxine XR daily Duloxetine mg daily, max 120 mg/day Paroxetine 20 mg QHS, max 50 mg/day, max elderly 40mg/day, Escitalopram 10 mg daily, max 20 mg/day, max elderly 10 mg/day Not FDA approved Sertraline daily Fluoxetine daily Second Line Benzodiazepines Diazepam 2-10 mg BID-TID Alprazolam mg TID, max 4 mg/day; elderly start 0.25 mg BID-TID Lorazepam 2-6 mg divided BID-TID, max 10 mg/day; elderly start 1-2 mg BID-TID Clonazepam mg BID-TID, max 4 mg/day Non-Benzodiazepines Buspirone mg divided BID-TID, max 60 mg/day 15

16 Guideline Recommendations Treatment Options FDA approved Hydroxyzine Medications q6h, max 600 mg Other Medications Augmentation Not FDA approved Imipramine mg daily, elderly max 100 mg/day Trazodone mg BID-TID, max 400/day Mirtazapine mg daily Bupropion XL mg daily Pregabalin mg divided BID-TID Quetiapine mg daily Vortioxetine 5 mg daily ot FDA approved) Olanzapine 5-10 mg daily Risperidone mg daily Quetiapine see above Pregabalin see above PTSD Symptoms to Pharmacology 16

17 DSM IV vs DSM V PTSD and Incident HF HR = 1.47; 95% CI: Am J Public Health. 2015;105: PTSD/HF/Risk Factors Age Diabetes Risk Factors Hypertension Overweight Obesity Combat Service Odds Ratio Am J Public Health. 2015;105:

18 Hypotheses of PTSD in HF Am J Physiol Regul Integr Comp Physiol 2015;309:R315-R321 Guideline Recommendations Pharmacotherapy For adult patients with PTSD, the panel suggests that clinicians offer one of the following (listed alphabetically): fluoxetine paroxetine sertraline venlafaxine There is insufficient evidence to recommend for or against clinicians offering the following medications (listed alphabetically) for treatment of adults with PTSD. risperidone topiramate For adult patients with PTSD, the panel recommends clinicians offering either venlafaxine ER or sertraline when both are being considered Strength of Recommendation Conditional Insufficient Strong For 18

19 Conclusions and Questions 19

Quick Guide to Common Antidepressants-Adults

Quick Guide to Common Antidepressants-Adults Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa

More information

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Treatment of Anxiety (without benzos)

Treatment of Anxiety (without benzos) Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Mixing and Matching: Layering Medications as Family Physicians

Mixing and Matching: Layering Medications as Family Physicians Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples

More information

Psychiatry in Primary Care: What is the Role of Pharmacist?

Psychiatry in Primary Care: What is the Role of Pharmacist? Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure

More information

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Depression in Late Life

Depression in Late Life Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

Common Antidepressant Medications for Adults

Common Antidepressant Medications for Adults (and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450

Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1

More information

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Psychiatry curbside: Answers to a primary care doctor s top mental health questions Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic

More information

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant

More information

Major Depression and Anxiety in Adolescents and Adults

Major Depression and Anxiety in Adolescents and Adults Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize

More information

Pharmacological Treatment of Anxiety & Depressive Disorders

Pharmacological Treatment of Anxiety & Depressive Disorders Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected. KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine

More information

Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015

Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015 49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Division of Psychosocial Oncology Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Epidemiology Lifetime

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual

More information

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic

More information

Child & Adolescent Psychiatry (a brief overview)

Child & Adolescent Psychiatry (a brief overview) Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina

More information

foreword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines

foreword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines Clinical Updates Management of Anxiety Disorders John So - Psychiatrist foreword Six Persimmons 六柿圖 MuqiFachang 牧谿法常 after Zen meditation mindfulness other trends of psychotherapy other modalities of treatments

More information

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

More information

Eligible Beneficiaries

Eligible Beneficiaries Therapeutic Class: Behavioral Health Medications for Adults Clinical Edit Number Long Description 4110 (May change) Quantity limit edit that is applied to atypical antipsychotics for claims identified

More information

Case #1. Case #1. Case #1. Discussion. DSM IV Overview of PD. Psychopharmacology of Panic Disorder and Generalized Anxiety Disorder 09/03/2012

Case #1. Case #1. Case #1. Discussion. DSM IV Overview of PD. Psychopharmacology of Panic Disorder and Generalized Anxiety Disorder 09/03/2012 Case #1 Psychopharmacology of Panic Disorder and Generalized Anxiety Disorder Smit S. Sinha MD Assistant Professor A 33 year old male engineer presents to an outpatient clinic for consultation for severe

More information

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY 13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD

More information

VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module

VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress Core Module Module A Acute Stress Continue Treatment for ASD Treatment for ACUTE Stress Disorder Module B PTSD Continue Treatment

More information

Mentoring Session: Participant Cases

Mentoring Session: Participant Cases Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants

More information

Adult Depression - Clinical Practice Guideline

Adult Depression - Clinical Practice Guideline 1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

Prescribing Medications for Anxiety and Depression (without getting anxious and depressed)

Prescribing Medications for Anxiety and Depression (without getting anxious and depressed) Prescribing Medications for Anxiety and Depression (without getting anxious and depressed) Stephen Warnick Jr., M.D. Assistant Professor Departments of Family Medicine and Psychiatry Disclosures None 2

More information

Katee Kindler, PharmD, BCACP

Katee Kindler, PharmD, BCACP Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,

More information

Optimal Treatment of Anxiety Disorders

Optimal Treatment of Anxiety Disorders Optimal Treatment of Anxiety Disorders Franklin R. Schneier, MD Co-Director, Anxiety Disorders Clinic Research Psychiatrist New York State Psychiatric Institute Special Lecturer in Psychiatry Columbia

More information

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.

More information

UPDATE ON PTSD PHARMACOTHERAPY: IS THERE ANYTHING THAT WORKS BETTER THAN SSRIS FOR PTSD?

UPDATE ON PTSD PHARMACOTHERAPY: IS THERE ANYTHING THAT WORKS BETTER THAN SSRIS FOR PTSD? Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences UPDATE ON PTSD PHARMACOTHERAPY: IS THERE ANYTHING THAT WORKS BETTER THAN SSRIS FOR PTSD? ASHLEY DAVIDSON, MD PSYCHIATRY

More information

GENERALIZED ANXIETY DISORDER (GAD) PRACTICE PRINCIPLE FOR PRIMARY CARE: ADULTS 18 AND OLDER

GENERALIZED ANXIETY DISORDER (GAD) PRACTICE PRINCIPLE FOR PRIMARY CARE: ADULTS 18 AND OLDER Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013

For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please

More information

Dr.Rahiminejad Roozbeh Hospital TUMS

Dr.Rahiminejad Roozbeh Hospital TUMS Dr.Rahiminejad Roozbeh Hospital TUMS Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications.

More information

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S. BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation

More information

Depression & Anxiety in Adolescents

Depression & Anxiety in Adolescents Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with

More information

Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)

Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Protocol Title: Depression & Generalized Anxiety Disorder Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Group

More information

Joe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health

Joe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health Joe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health Solutions, PLLC www.bartoncbt.com Academic and Pop-Culture

More information

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure

More information

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors* Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ANXIETY DISORDERS This guideline covers a range of anxiety disorders, including generalised anxiety disorder, social

More information

Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD)

Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD) 1 Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD) This continuing education monograph examines the results of a comparative effectiveness review to assess

More information

TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness

TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness DATE: 03 May 2012 CONTEXT AND POLICY ISSUES Generalized Anxiety Disorder (GAD) is a chronic

More information

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty

More information

Family Medicine Forum Montreal, Quebec November 11, Jon Davine, CCFP, FRCP(C) McMaster University

Family Medicine Forum Montreal, Quebec November 11, Jon Davine, CCFP, FRCP(C) McMaster University ANXIETY DISORDERS Family Medicine Forum Montreal, Quebec November 11, 2017. Jon Davine, CCFP, FRCP(C) McMaster University DISCLOSURE Speaker/Presenter Disclosure Not applicable Disclosure of Commercial

More information

Use of Psychotropic Medications in Older Adults with Dementia!

Use of Psychotropic Medications in Older Adults with Dementia! Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with

More information

New Patient Questionnaire

New Patient Questionnaire 4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with

More information

Objectives: Lifetime prevalence. Neurotransmitters of interest

Objectives: Lifetime prevalence. Neurotransmitters of interest Kelly Kll M. Rock, DNP, CRNP 11/5/11 Objectives: Identify lifetime prevalence of depressive and anxious disorders. Recognize the social and economic burden of depressive and anxious disorders. Understand

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Partners in Care Quick Reference Cards

Partners in Care Quick Reference Cards Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly

More information

Augmentation and Combination Strategies in Antidepressants treatment of Depression

Augmentation and Combination Strategies in Antidepressants treatment of Depression Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported

More information

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine

More information

PSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust

PSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions

More information

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

NorthSTAR. Pharmacy Manual

NorthSTAR. Pharmacy Manual NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics

More information

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care? Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious

More information

Post-traumatic stress disorder

Post-traumatic stress disorder National Institute for Health and Care Excellence Final Post-traumatic stress disorder [F] Evidence reviews for pharmacological interventions for the prevention and treatment of PTSD in adults NICE guideline

More information

Objectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System

Objectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate

More information

Volume 4; Number 5 May 2010

Volume 4; Number 5 May 2010 Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated

More information

Panic disorder is a chronic and recurrent illness associated

Panic disorder is a chronic and recurrent illness associated CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional

More information

Depression in Pregnancy

Depression in Pregnancy TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date

More information

Treatment of Mood Disorders in Midlife Women

Treatment of Mood Disorders in Midlife Women Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN

More information

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)

More information

Hazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke

Hazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke By Michael Dixon Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any

More information

PSYCHIATRY INTAKE FORM

PSYCHIATRY INTAKE FORM Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.

More information

Depression: Identification, Evaluation and Management in Primary Care

Depression: Identification, Evaluation and Management in Primary Care Depression: Identification, Evaluation and Management in Primary Care Primary Care Update: 2013 I have nothing to disclose Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California,

More information